Rapport Therapeutics RAPP
NASDAQ RAPP
$25.25 -4.12 (-14.03%)
As of: Oct 21, 2026 · 3:31 PM EDT

Rapport Therapeutics (RAPP) Receivables - Net (2026)

Updated

Rapport Therapeutics' Receivables - Net was $300,000 in Q2 2026, up 417.2% from the prior quarter.

Analysis

Rapport Therapeutics (RAPP) Receivables - Net (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.26 Bn 1,105.84 Bn 19.71 Bn
2 Johnson & Johnson 618.12 Bn 536.65 Bn 17.26 Bn
3 AbbVie 503.25 Bn 476.36 Bn 12.70 Bn
4 Merck 368.28 Bn 322.66 Bn 12.21 Bn
5 Novartis Ag 298.45 Bn 262.44 Bn 11.24 Bn
6 Astrazeneca 261.39 Bn 235.08 Bn 12.86 Bn
7 Amgen 237.30 Bn 192.70 Bn 7.24 Bn
8 Gilead Sciences 191.35 Bn 165.55 Bn 6.22 Bn
9 Pfizer 169.92 Bn 116.56 Bn 10.94 Bn
10 Rapport Therapeutics 1.20 Bn 381.46 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 300,000.00
Mar 31, 2026 58,000.00
API Access

Rapport Therapeutics Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=RAPP&period=max&api_key=YOUR_API_KEY